Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (621-630 of 1,211) with videos related to

Pageof 122
Sort By:
Circulation|June 22, 2005
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarctionScott D Solomon, Hicham Skali, Nagesh S Anavekar, et al.
Journal of the American College of Cardiology|October 29, 2013
Lipoprotein(a) for risk assessment in patients with established coronary artery diseaseMichelle L O'Donoghue, David A Morrow, Sotirios Tsimikas, et al.
Circulation. Heart Failure|November 9, 2020
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?Su E Yeoh, Pooja Dewan, Pardeep S Jhund, et al.
European Journal of Heart Failure|June 8, 2021
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trialAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|October 5, 2019
Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term OutcomesElke Platz, Ross T Campbell, Brian Claggett, et al.
European Journal of Heart Failure|August 27, 2023
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVERJawad H Butt, Henri Lu, Toru Kondo, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Circulation. Heart Failure|March 3, 2025
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection FractionMingming Yang, Toru Kondo, Pooja Dewan, et al.
European Journal of Heart Failure|August 21, 2014
Impaired left atrial function in heart failure with preserved ejection fractionAngela B S Santos, Elisabeth Kraigher-Krainer, Deepak K Gupta, et al.
JAMA Cardiology|August 25, 2018
Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 122

Showing results (621-630 of 1,211) with videos related to

Sort By:
Pageof 122
Circulation|June 22, 2005
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarctionScott D Solomon, Hicham Skali, Nagesh S Anavekar, et al.
Journal of the American College of Cardiology|October 29, 2013
Lipoprotein(a) for risk assessment in patients with established coronary artery diseaseMichelle L O'Donoghue, David A Morrow, Sotirios Tsimikas, et al.
Circulation. Heart Failure|November 9, 2020
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?Su E Yeoh, Pooja Dewan, Pardeep S Jhund, et al.
European Journal of Heart Failure|June 8, 2021
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trialAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|October 5, 2019
Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term OutcomesElke Platz, Ross T Campbell, Brian Claggett, et al.
European Journal of Heart Failure|August 27, 2023
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVERJawad H Butt, Henri Lu, Toru Kondo, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Circulation. Heart Failure|March 3, 2025
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection FractionMingming Yang, Toru Kondo, Pooja Dewan, et al.
European Journal of Heart Failure|August 21, 2014
Impaired left atrial function in heart failure with preserved ejection fractionAngela B S Santos, Elisabeth Kraigher-Krainer, Deepak K Gupta, et al.
JAMA Cardiology|August 25, 2018
Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 122